Abstract
Biological drugs are products made from biological active substances. When the patents protecting these drugs expire, biosimilar drugs can be developed by other manufacturers. To carry out an inventory of the economic and regulatory aspects of biomedicines in Morocco, and to give an overview of the different biological drugs and their biosimilars available, we based our work on a bibliographic search and on the use of different drug databases available in Morocco. In Morocco, a regulatory framework has framed the administrative procedure for the marketing authorization of biological drugs and their biosimilars. Biological drugs available on the Moroccan market belong to several classes and the health insurance system covers the majority of them. In Morocco, industrial companies must be encouraged to locally produce biomedicines. This would allow covering part of the national needs and reducing costs, which will increase patients´ access to such drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
